Saatchi to Lose Remainder of Its J&J Brands | Adweek
Advertisement

Saatchi to Lose Remainder of Its J&J Brands

Advertisement

NEW YORK Publicis Groupe's Saatchi & Saatchi, already eliminated in the review for creative chores on Tylenol's estimated $115 million account, is losing ad duties on the three other Johnson & Johnson brands it handles: Pepcid, Mylanta and St. Joseph aspirin, an agency representative confirmed. Spending on those brands is estimated at $75 million.

It's unclear where the brands will land. But under one scenario, they could shift wholesale to another roster shop, such as Interpublic Group's Alchemy in New York, sources said. A Saatchi rep acknowledged that the business was leaving but declined further comment. The client could not immediately be reached and Alchemy did not return calls.

Tylenol, Pepcid, Mylanta and St. Joseph are part of the McNeil consumer and specialty pharmaceuticals division of J&J. Alchemy already handles several McNeil brands, including Motrin, Immodium and Nizoral.

A decision in the Tylenol review, meanwhile, is expected next week, following another round of presentations on Friday and Monday, said sources. The finalists, which emerged from a field of six, are all IPG shops: The Martin Agency in Richmond, Va., Hill, Holliday, Connors, Cosmopulos in Boston and Deutsch in New York.